全植入式曲前列尼尔静脉输注系统治疗肺动脉高压的植入操作评估
多中心前瞻性单臂临床试验(DelIVery for PAH)纳入64例稳定接受静脉曲前列尼尔治疗的PAH患者,评估全植入式静脉输注系统的植入操作。60例植入手术全部成功,平均耗时102±32分钟,临床显著并发症包括1例气胸、2例感染和1例房颤。
要点
- 全植入式静脉曲前列尼尔输注系统植入手术成功率高,60例均成功。
- 临床显著植入相关并发症少见,包括气胸、感染和房颤。
- 常见非并发症事件为植入部位疼痛(83%)和瘀斑(17%)。
核心结论
- 全植入式曲前列尼尔静脉输注系统的植入操作可成功完成,并发症较少。
研究设计与样本
- 多中心、前瞻性、单臂临床试验(DelIVery for PAH),纳入64例WHO第1组PAH患者,在10个中心由不同专科医生在全身麻醉或深度静脉镇静下进行植入。
主要发现
- 64例中4例在植入前退出,60例植入手术全部成功。
- 基线时所有患者经外部泵接受曲前列尼尔,平均剂量71.4 ± 27.8 ng/kg/min(范围22-142 ng/kg/min)。
- 植入手术平均耗时102 ± 32分钟(范围47-184分钟)。
- 临床显著植入相关并发症包括1例气胸、2例感染和1例房颤。
- 两例患者发生3次植入后导管脱位;非并发症常见事件为植入部位疼痛(83%)和瘀斑(17%)。
临床怎么用
- 对于稳定接受静脉曲前列尼尔治疗的PAH患者,可考虑全植入式输注系统,需注意植入相关并发症和导管脱位风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In response to risks associated with external delivery systems, an implantable IV infusion system was developed. A multicenter, prospective, single-arm, clinical trial (DelIVery for PAH) was conducted to evaluate this system for treprostinil in PAH. This analysis describes the findings related to the implant procedure. METHODS: Patients (N = 64) with PAH (World Health Organization group 1) receiving stable IV treprostinil were enrolled. Patients were transitioned to a temporary peripheral IV infusion catheter prior to the procedure. System implantation was performed at 10 centers under general anesthesia or deep IV sedation by clinicians from various specialties. Central venous access was via the cephalic, subclavian, jugular, or axillary vein. Using an introducer and fluoroscopic guidance, the distal tip of the infusion catheter was placed at the superior caval-atrial junction. The catheter was tunneled from the venous access site to an abdominal subcutaneous pocket, where the pump was placed. RESULTS: Of the 64 patients enrolled, four exited prior to implantation. All 60 implant procedures were successful. At baseline, all patients were receiving treprostinil via an external pump at a mean dose of 71.4 ± 27.8 ng/kg/min (range: 22-142 ng/kg/min). The implant averaged 102 ± 32 min (range: 47-184 min). Clinically significant implant procedure-related complications included one pneumothorax, two infections, and one episode of atrial fibrillation. There were three postimplantation catheter dislocations in two patients. Common implant-related events that were not complications included implant site pain (83%) and bruising (17%). CONCLUSIONS: The procedure for inserting a fully implantable system for treprostinil was successfully performed, with few complications. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01321073; URL: www.clinicaltrials.gov.
引用
- Waxman AB, McElderry HT, Gomberg-Maitland M, et al. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. Chest. 2017. PMID: 28583617. doi:10.1016/j.chest.2017.04.188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。